Spyre's SPY003 Hits Primary Endpoint in UC, Completing POC for All Three IBD Components
SYRE has more than doubled off its 52-week low of $14.505.
Summary
Spyre reported positive Phase 2 SKYLINE Part A induction data for SPY003 (anti-IL-23) in ulcerative colitis. The drug met its primary endpoint with a statistically significant 10.0-point reduction in RHI score (p<0.0001), along with 20% clinical remission and 30% endoscopic improvement. Safety was consistent with the IL-23 class, with no drug-related serious adverse events. This completes proof-of-concept for all three components of Spyre's IBD combination strategy, following earlier positive data for SPY001 and SPY002. The company is now enrolling Part B of SKYLINE, which will test pairwise combinations, with topline data expected in 2027. This milestone strengthens the rationale for the combination approach and positions Spyre as a leader in next-generation IBD therapies.
At the time of this announcement, SYRE was trading at $88.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $14.51 to $110.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.